ABSTRACT:
This a model from the article:
Mechanisms of abnormal calcium homeostasis in mutations responsible for
catecholaminergic polymorphic ventricular tachycardia.
Iyer V, Hajjar RJ, Armoundas AA. Circ Res
2007 Feb 2;100(2):e22-31 17234962
,
Abstract:
Catecholaminergic polymorphic ventricular tachycardia is a heritable arrhythmia
unmasked by exertion or stress and is characterized by triggered activity and
sudden cardiac death. In this study, we simulated mutations in 2 genes linked to
catecholaminergic polymorphic ventricular tachycardia, the first located in
calsequestrin (CSQN2) and the second in the ryanodine receptor (RyR2). The aim
of the study was to investigate the mechanistic basis for spontaneous Ca2+
release events that lead to delayed afterdepolarizations in affected patients.
Sarcoplasmic reticulum (SR) luminal Ca2+ sensing was incorporated into a model
of the human ventricular myocyte, and CSQN2 mutations were modeled by simulating
disrupted RyR2 luminal Ca2+ sensing. In voltage-clamp mode, the mutant CSQN2
model recapitulated the smaller calcium transients, smaller time to peak calcium
transient, and accelerated recovery from inactivation seen in experiments. In
current clamp mode, in the presence of beta stimulation, we observed delayed
afterdepolarizations, suggesting that accelerated recovery of RyR2 induced by
impaired luminal Ca2+ sensing underlies the triggered activity observed in
mutant CSQN2-expressing myocytes. In current-clamp mode, in a model of mutant
RyR2 that is characterized by reduced FKBP12.6 binding to the RyR2 on beta
stimulation, the impaired coupled gating characteristic of these mutations was
modeled by reducing cooperativity of RyR2 activation. In current-clamp mode, the
mutant RyR2 model exhibited increased diastolic RyR2 open probability that
resulted in formation of delayed afterdepolarizations. In conclusion, these
minimal order models of mutant CSQN2 and RyR2 provide plausible mechanisms by
which defects in RyR2 gating may lead to the cellular triggers for arrhythmia,
with implications for the development of targeted therapy.
This model was taken from the CellML repository
and automatically converted to SBML.
The original model was:
Iyer V, Hajjar RJ, Armoundas AA. (2007) - version=1.0
The original CellML model was created by:
Penny Noble
penny.noble@dpag.ox.ac.uk
The University of Oxford
This model originates from BioModels Database: A Database of Annotated Published Models (http://www.ebi.ac.uk/biomodels/). It is copyright (c) 2005-2011 The BioModels.net Team.
To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication
for more information.
In summary, you are entitled to use this encoded model in absolutely any manner you deem suitable, verbatim, or with modification, alone or embedded it in a larger context, redistribute it, commercially or not, in a restricted way or not.
.
To cite BioModels Database, please use: Li C, Donizelli M, Rodriguez N, Dharuri H, Endler L, Chelliah V, Li L, He E, Henry A, Stefan MI, Snoep JL, Hucka M, Le Novère N, Laibe C (2010) BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models. BMC Syst Biol., 4:92.